It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

Analysts, who are highly bullish on the stock, have fretted for some time that Viking needed a partner to actually make the ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Viking Therapeutics seems to be doubling down on its hopes of making waves in the weight management market as a stand-alone ...

Under the deal, CordenPharma will crank out long-term supply of both the subcutaneous and oral versions of Viking’s experimental drug. The oral formulation of VK2735 is currently in a 13-week ...

Viking Therapeutics ( VKTX -0.30%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its investigational obesity drug, VK2735, as the biotech positions itself to ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

And Viking said it has worked with Corden in the past, although it declined to specify on which drug. Under the terms of the deal, Viking will make prepayments to Corden of $150 million over the ...